Patents by Inventor Michael Hallek

Michael Hallek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070027167
    Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.
    Type: Application
    Filed: September 5, 2006
    Publication date: February 1, 2007
    Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
  • Patent number: 7078478
    Abstract: Multiple myeloma is treated by deletion mutants of the gp130 protein of the IL-3 receptor. These mutants inhibit the binding of Hck tyrosine kinase and the growth of tumor cells, particularly myeloma cells.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: July 18, 2006
    Assignee: GSF-Forschungszentrum für Umwelt Gesundheit, GmbH
    Inventors: Michael Schaeffer, Michaela Schneiderbauer, Sascha Weidler, Michael Hallek
  • Publication number: 20060148058
    Abstract: The tides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit they tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
    Type: Application
    Filed: January 31, 2006
    Publication date: July 6, 2006
    Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Ottmann, Markus Warmuth
  • Publication number: 20060074094
    Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.
    Type: Application
    Filed: November 22, 2005
    Publication date: April 6, 2006
    Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
  • Patent number: 7001765
    Abstract: The present invention provides an Adeno-Associated Virus (AAV) vector having a foreign DNA coding for a protein that boosts immunogenicity of cells. The invention also provides a vaccine containing such a vector and the use of both.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: February 21, 2006
    Assignee: Medigene AG
    Inventors: Gerhard Maass, Michael Hallek, Christoph Bogedain
  • Publication number: 20050249745
    Abstract: Vaccine formulations comprising, viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
    Type: Application
    Filed: July 13, 2005
    Publication date: November 10, 2005
    Inventors: Michael Hallek, Alexander Burger
  • Patent number: 6926897
    Abstract: The invention relates to a medicament for preventing or treating human papilloma virus (HPV)-specific tumors containing at least one fusion protein and optional suitable additives and/or auxiliary agents. Said fusion protein is comprised of at least one L1-protein of one or more papilloma viruses, and is also comprised of at least one E-protein of one or more papilloma viruses, whereby the fusion protein does not contain any papilloma virus non-specific epitopes.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: August 9, 2005
    Assignee: MediGene Aktiengesellschaft
    Inventors: Alexander Burger, Michael Hallek
  • Publication number: 20050106558
    Abstract: This invention relates to a library of nucleic acids comprising a multiplicity of expressible structural genes, preferably cap genes, from an eukaryotic virus, preferably of a parvovirus.
    Type: Application
    Filed: December 23, 2002
    Publication date: May 19, 2005
    Inventors: Luca Perabo, Hildegard Buring, Jorg Enssle, Martin Ried, Michael Hallek, Nadja Huttner
  • Publication number: 20050031637
    Abstract: The present invention relates to a pharmaceutical composition for the avoidance or treatment of human papillomavirus (HPV)-specific tumour comprising at least one fusion protein from at least one L1 protein of one or more papillomaviruses and at least one E protein of one or more papillomaviruses, the fusion protein containing no papillomavirus-unspecific epitopes. In some embodiments, the pharmaceutical composition further comprises suitable additives and/or excipients.
    Type: Application
    Filed: June 29, 2004
    Publication date: February 10, 2005
    Inventors: Alexander Burger, Michael Hallek
  • Patent number: 6846665
    Abstract: The present invention relates to a method for producing a recombinant adeno-associated virus (rAAV), in which at different times a helper construct and also a vector construct are introduced into a suitable cell, and preferably the helper construct does not comprise, in particular with the exception of the AAV promoters, any nucleic acid sequences to which at least a Rep protein can essentially specifically bind and preferably the vector construct comprises ITR sequences in flop orientation. The recombinant adeno-associated viruses produced according to the method of the invention are suitable in particular for producing a tumor cell into which additionally nucleic acids coding for GM-CSF and B7.2 has been introduced, which in turn can be used in the form of a medicament for the treatment of cancers.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: January 25, 2005
    Assignee: MediGene Aktiengesellschaft
    Inventors: Markus Hörer, Michael Hallek
  • Publication number: 20050002908
    Abstract: The present invention relates to a method for producing a recombinant adeno-associated virus (rAAV), in which at different times a helper construct and also a vector construct are introduced into a suitable cell, and preferably the helper construct does not comprise, in particular with the exception of the AAV promoters, any nucleic acid sequences to which at least a Rep protein can essentially specifically bind and preferably the vector construct comprises ITR sequences in flop orientation. The recombinant adeno-associated viruses produced according to the method of the invention are suitable in particular for producing a tumor cell into which additionally nucleic acids coding for GM-CSF and B7.2 has been introduced, which in turn can be used in the form of a medicament for the treatment of cancers.
    Type: Application
    Filed: July 12, 2004
    Publication date: January 6, 2005
    Inventors: Markus Horer, Michael Hallek
  • Publication number: 20040161418
    Abstract: The present invention provides an Adeno-Associated Virus (AAV) vector having a foreign DNA coding for a protein that boosts immunogenicity of cells. The invention also provides a vaccine containing such a vector and the use of both.
    Type: Application
    Filed: October 16, 2003
    Publication date: August 19, 2004
    Inventors: Gerhard Maass, Michael Hallek, Christoph Bogedain
  • Publication number: 20040081661
    Abstract: Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
    Type: Application
    Filed: September 4, 2003
    Publication date: April 29, 2004
    Applicant: Medigene AG
    Inventors: Michael Hallek, Alexander Burger
  • Patent number: 6649167
    Abstract: Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: November 18, 2003
    Assignee: Medigene AG
    Inventors: Michael Hallek, Alexander Burger
  • Publication number: 20030170851
    Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
    Type: Application
    Filed: October 3, 2002
    Publication date: September 11, 2003
    Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth
  • Publication number: 20030162222
    Abstract: The invention relates to a method of selecting inhibitors for enzymes and use of the selected inhibitor as a therapeutic and/or prophylactic agent, a mutant which can be used in the method and a method of testing an inhibitor for its specificity in a modelling system.
    Type: Application
    Filed: March 24, 2003
    Publication date: August 28, 2003
    Inventors: Markus Warmuth, Ruth Mathes, Michael Hallek
  • Patent number: 6605703
    Abstract: The present invention describes a means for the treatment of multiple myeloma. Deletion mutants of the gp130 protein of the IL-3 receptor are presented which inhibit the binding of Hck tyrosine kinase and the growth of tumor cells, particularly of myeloma cells.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: August 12, 2003
    Assignee: GSF—Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Michael Schaeffer, Michaela Schneiderbauer, Sascha Weidler, Michael Hallek
  • Publication number: 20030105287
    Abstract: Multiple myeloma is treated by deletion mutants of the gp130 protein of the IL-3 receptor. These mutants inhibit the binding of Hck tyrosine kinase and the growth of tumor cells, particularly myeloma cells.
    Type: Application
    Filed: July 12, 2002
    Publication date: June 5, 2003
    Applicant: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Michael Schaeffer, Michaela Schneiderbauer, Sascha Weidler, Michael Hallek
  • Patent number: 6562351
    Abstract: Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: May 13, 2003
    Assignee: Medigene AG
    Inventors: Michael Hallek, Alexander Burger
  • Patent number: 6541012
    Abstract: The invention concerns a system comprising an AAV vector, which contains a foreign DNA, and rep 68/78 sequences of AAV with delayed expression, these sequences being present (a) in cis or (b) in trans. The invention also concerns the use of such a system for the production of AAV vectors.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: April 1, 2003
    Inventors: Christoph Bogedain, Gerd Maass, Michael Hallek